Escolar Documentos
Profissional Documentos
Cultura Documentos
Abstract
Background: Inconclusive protocol and consensus exist at present time regarding treatment of patients who have de-
veloped Osteonecrosis of the Jaw (ONJ) following administration of intravenous Bisphosphonates. Most clinicians are
avoiding treatment for patients presenting with BRONJ due to lack of predictable treatment outcome.
Findings: In this case report, patient was suffering from a non healing lesion on anterior mandible, which was not re-
sponsive to any conventional treatment. Patient was recommended to rinse with the PBSCD for treatment of BRONJ
(Bisphosphonate Related Osteonecrosis of the Jaw) lesion seen on some patients who were on intravenous Bisphos-
phonate medications for multiple myeloma. Patient was recommended to rinse three times a day with PBSCD. After 4
month use of the solution patient presented with soft tissue healing on previously exposed necrotic bone on mandibu-
lar anterior region.
Conclusion: The benefit of Phosphate buffer-stabilized 0.1% chlorine dioxide-containing mouth wash (PBSCD) is dis-
cussed. This is a non invasive protocol that has proved to be effective in closing of an open wound.
© Under License of Creative Commons Attribution 3.0 License This article is available from: http://www.transbiomedicine.com
2010
iMedPub Journals TRANSLATIONAL BIOMEDICINE Vol.1
No. 1:7
doi: 10:3823/406
Also, through continued research and reports on the subject chief complained remained unresolved as how to close the open
matter, more successful treatment plans will arise. wound, which was easy for patient to see it on a daily basis.
Case:
Patient is a 64 year old African American with a history of long
term use of IV Bisphosphonate. The medical consultation with
the patient’s hematologist/oncologist revealed that the patient
was diagnosed with multiple myeloma in early 2005 and initially
started on Dexamethasone and had received 4 mg zoledronic
acid treatments intravenously, on a monthly basis, until January
2007 (six month post-extraction of tooth # 24 and two years
post treatment with zoledronic acid), when the treating medi-
cal personnel had discovered the emergence of ONJ. However,
the discontinuation of zoledronic acid treatments in January
2007 did not help our patient. This finding is in agreement with
Ruggiero et al, whom stated that “there is no evidence to sug-
gest interrupting bisphosphonate therapy will prevent or lower
the risk of ONJ.”12,13 Clinical (Figure 1) and radiographic (Figure
2) evaluation revealed 2 x 4 x 2 mm size lesion on extraction Figura 2
site, which was asymptomatic and stable in Feb 2008. Three
dimensional image of the area revealed break in cortical plate
and a non healing socket (Figure 3). The lesion became aggres- Patient was instructed to rinse with the PBSCD (CloSYS II-Rowpar
sive and increased in size (Figure 4). Patient called and stated Pharmaceuticals) for 30 second three times a day. Four month
that he has aches and pain on mandibular anterior area. later patient presented to our office with the necrotic bone in
his hand (Figure 5). Patient was happy with the mouth wash
and stated that the rinse helped him getting rides of the loose
bone. Clinical evaluation disclosed complete soft tissue healing
on previously exposed necrotic bone on mandibular anterior
region (Figure 6). We recommend this product. Our results are
in agreement with the previous report by Marder (2009) that
the PBSCD has potential rinsing solution to facilitate release of
necrotic bone and closure of an open wound.
Figura 1
Patient was treated with Augmentin 500 mg 30 tab I. P.O. TID and
Chlorohexidine16oz rinse twice daily. Patient response was po-
sitive and stated that he felt much better. Aches were gone but Figura 3
© Under License of Creative Commons Attribution 3.0 License This article is available from: http://www.transbiomedicine.com
2010
iMedPub Journals TRANSLATIONAL BIOMEDICINE Vol.1
No. 1:7
doi: 10:3823/406
Figura 6
References
© Under License of Creative Commons Attribution 3.0 License This article is available from: http://www.transbiomedicine.com
2010
iMedPub Journals TRANSLATIONAL BIOMEDICINE Vol.1
No. 1:7
doi: 10:3823/406
bone necrosis. J Clin Oncol 2003;21(22):4253-4. 9. Calvo-Villas JM .Osteonecrosis of the jaw in patients with mul-
3. Woo SB. Osteonecrosis of the jaw and bisphosphonates. N tiple myeloma during and after treatment with zoledronic acid.
Engl J Med 2005;353(1):99-102. Med Clin (Barc). 2006 Oct 21;127(15):576-9.
4. Wang J. Osteonecrosis of the jaws associated with cancer 10. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Ra-
chemotherapy. J Oral Maxillofac Surg 2003;61(9):1104-7. poport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteo-
5. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: necrosis of the jaw in multiple myeloma patients: clinical featu-
bisphosphonates and osteonecrosis of the jaws. Ann Intern res and risk factors. J Clin Oncol. 2006 Feb 20;24(6):945–52.
Med. 2006 May 16;144(10):753–61. Erratum in: Ann Intern Med. 11. Ruggiero SL. Osteonecrosis of the jaws associated with the
2006 Aug 1;145(3):235. use of bisphosphonates: a review of 63 cases. J Oral Maxillofac
6. Gralow J. Evolving role of bisphosphonates in women under- Surg 2004;62(5):527-34.
going treatment for localized and advanced breast cancer. Clin 12. Ruggiero SL. Practical guidelines for the prevention, diag-
Breast Cancer 2005; 5 Suppl(2):S54-62. nosis and treatment of osteonecrosis of the jaw in patients with
7. Bagan JV. Avascular jaw osteonecrosis in association with cancer. J Oncology Practice 2006;2(1):7-14.
cancer chemotherapy: series of 10 cases. J Oral Pathol Med 13. Edwards BJ et al: Updated recommendations for managing
2005;34(2):120-3. the care of patients receiving oral bisphosphonate therapy.
8. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melako- JADA 2008; 139(12):1674-1677
poulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos 14. Marder, MZ, Marder, RW: Bisphosphonate-Associated Os-
K, Bamias A. Osteonecrosis of the jaw in patients with multiple teonecrosis Experiences in a Private Practice: Dent Today; Oct
myeloma treated with bisphosphonates: evidence of increased 2008, 27 (10)99-103
risk after treatment with zoledronic acid. Haematologica. 2006 15. Glick M. Closing in on the Puzzle of ONJ. J Am Dent Assoc.
Jul;91(7):968-71. 2008; 139: 12-15.
http://www.imedpub.com
http://www.transbiomedicine.com
© Under License of Creative Commons Attribution 3.0 License This article is available from: http://www.transbiomedicine.com